This article is more than 5 years old. Information may no longer be current.

No dosing equivalency ratio found between Xeomin, Dysport

Researchers found no precise ratios could be determined when attempting to establish a dosing equivalency for Dysport and Xeomin that would result in similar clinical effectiveness and patient satisfaction.

The study included 32 patients who previously received at least four consecutive treatments of Dysport (abobotulinumtoxin A, aboBTX-A, Galderma) at 4-month intervals in the prior 12 months, achieving 85% to 90% elimination of dynamic glabellar frown lines and who expressed satisfaction with at least four consecutive treatments.

In an attempt to establish a dose comparison between established maintenance aboBTX-A dosing and Xeomin (incobotulinumtoxin A, incoBTX-A, Merz) first-time dosing, the researchers selected a 2:1 conversion (aboBTX-A:incoBTX-A) for most patients.

The study’s primary outcomes were patient-perceived clinical effectiveness at 2 weeks and percentage of muscle activity at 3 months per surgeon assessment, and secondary outcomes were patient-reported onset of effect, physician-assessed effect at 10 to 12 weeks, pain associated with administration and patient-perceived need for retreatment at 2 weeks.

Mean aboBTX-A treatment dose administered was 27.6, whereas mean treatment dose of incoBTX-A was 17.1 units.

Of the 32 patients studied, 29 (91%) reported satisfactory treatment effect at 2 weeks, and three patients (9%) requested retreatment with aboBTX-A at 2 weeks due to perceived lack of efficacy with incoBTX-A, according to the researchers.

Sixty-two percent of patients reported equivalent pain between the two treatments, whereas 22% reported more pain with incoBTX-A injection. Nine percent of patients reported less pain with incoBTX-A, and 6% were unable to reliably respond.

Overall satisfaction with incoBTX-A was reported by 68% of patients at 2 weeks, which increased to 78% at 3 months.

Among patients who received incoBTX-A at a ratio of 1.5-2.5:1, 40% had a clinical result that was considered equivalent to the original four aboBTX-A treatment doses. Additionally, 16% of patients had effects that were less than expected for the hypothesized ratio, according to the researchers. – by Abigail Sutton

Disclosures: The researchers report no relevant financial disclosures.